Synergistic celecoxib and dimethyl-celecoxib combinations block cervix cancer growth through multiple mechanisms
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0308233 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Diana Xochiquetzal Robledo-Cadena und 8 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Bioquímica, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, México. Hauptthemen laut MEDLINE: Celecoxib, Uterine Cervical Neoplasms, Cell Proliferation, Drug Synergism. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CONAHCyT-México, Universidad Nacional Autonoma de Mexico, National Institute of Chemical Physics and Biophysics (NICPB), Tallinn, Estonia.
Abstract (Originalsprache)
Objective
The synergistic inhibitory effect of celecoxib (CXB) and dimethyl-celecoxib (DMC) plus paclitaxel (PA) or cisplatin (CP) on human cervix HeLa and SiHa cells was assessed at multiple cellular levels in order to elucidate the biochemical mechanisms triggered by the synergistic drug combinations.
Methods
The effect of CXB (5 μM)/CP (2 μM) or CXB (5 μM)/PA (15 μM) and DMC (15 μM)/CP (5 μM) or DMC (15 μM)/PA (20 μM) for 24 h was assayed on cancer cell proliferation, energy metabolism, mitophagy, ROS production, glycoprotein-P activity, DNA stability and apoptosis/necrosis.
Results
Drug combinations synergistically decreased HeLa and SiHa cell proliferation (>75%) and arrested cellular cycle by decreasing S and G2/M phases as well as the Ki67 content (HeLa) by 7.5–30 times. Cell viability was preserved (>90%) and no apparent effects on non-cancer cell growth were observed. Mitochondrial and glycolytic protein contents (44–95%) and ΔΨm (45–50%) in HeLa cells and oxidative phosphorylation and glycolysis fluxes (70–90%) in HeLa and SiHa cells were severely decreased, which in turn promoted a drastic fall in the ATP supply (85–88%). High levels of mitophagy proteins in HeLa cells and active mitochondrial digestion in HeLa and SiHa cells was observed. Mitochondrial fission and microtubule proteins were also affected. Intracellular ROS content (2–2.3-fold) and ROS production was stimulated (2.3–4 times), whereas content and activity of glycoprotein-P (45–85%) were diminished. DNA fragmentation was not observed and apoptosis/necrosis was not detected suggesting that cell death could be mainly associated to mitophagy induction.
Conclusions
CXB or DMC combination with canonical chemotherapy may be a promising chemotherapy strategy against cervical cancer growth, because it can selectively block multiple cell processes including inhibition of energy pathways and in consequence ATP-dependent processes such as cell proliferation, glycoprotein-P activity, ROS production and mitophagy, with no apparent effects on non-cancer cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Departamento de Bioquímica, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, México.
- Posgrado en Ciencias Biológicas, Universidad Nacional Autónoma de México, Unidad de Posgrado, Edificio D, 1° Piso, Circuito de Posgrados, Ciudad Universitaria, Coyoacán, C.P. 04510, CDMX, México.
- Center for Preventive Cardiology, Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, United States of America.
- Laboratorio de Control Metabólico, Carrera de Biología de la Facultad de Estudios Superiores Iztacala, UNAM, Los Reyes Ixtacala, Hab Los Reyes Ixtacala Barrio de los Árboles/Barrio de los Héroes, Tlalnepantla, México.
- Departamento de Fisiología, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, México.
- Departamento de Biomedicina Cardiovascular, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, México.
ORCID-Profile: Diana Xochiquetzal Robledo-Cadena, Joaquín Alberto Padilla-Flores, Rebeca López-Marure, Tuuli Kaambre, Sara Rodríguez-Enríquez
Förderung
- CONAHCyT-México
- Universidad Nacional Autonoma de Mexico
- National Institute of Chemical Physics and Biophysics (NICPB), Tallinn, Estonia
Zitieren
APA
Robledo-Cadena, D. X., Pacheco-Velázquez, S. C., Vargas-Navarro, J. L., Padilla-Flores, J. A., López-Marure, R., Pérez-Torres, I., Kaambre, T., Moreno-Sánchez, R., & Rodríguez-Enríquez, S. (2024). Synergistic celecoxib and dimethyl-celecoxib combinations block cervix cancer growth through multiple mechanisms. PLOS ONE. https://doi.org/10.1371/journal.pone.0308233
Vancouver
Robledo-Cadena DX, Pacheco-Velázquez SC, Vargas-Navarro JL, Padilla-Flores JA, López-Marure R, Pérez-Torres I, et al. Synergistic celecoxib and dimethyl-celecoxib combinations block cervix cancer growth through multiple mechanisms. PLOS ONE. 2024. doi:10.1371/journal.pone.0308233
BibTeX
@article{RobledoCadena2024,
author = {Robledo-Cadena, Diana Xochiquetzal and Pacheco-Velázquez, Silvia Cecilia and Vargas-Navarro, Jorge Luis and Padilla-Flores, Joaquín Alberto and López-Marure, Rebeca and Pérez-Torres, Israel and Kaambre, Tuuli and Moreno-Sánchez, Rafael and Rodríguez-Enríquez, Sara},
title = {Synergistic celecoxib and dimethyl-celecoxib combinations block cervix cancer growth through multiple mechanisms},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0308233}
}
EUVIMED